Contents 2 min read

Claim and source comparison

Mucuna pruriens: a single-dose Parkinson’s study and measured levodopa in supplements.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

In the 2004 crossover trial, 8 people with Parkinson’s disease received single doses in separate sessions of a seed preparation and levodopa/carbidopa. With the studied 30 g preparation, motor effects began earlier and “on” time was longer.

There was no significant difference in dyskinesia or tolerability. This small, brief study does not establish long-term safety or cognitive benefit in healthy people.

Source 1 · Abstract read

Cell / laboratory study

In a 2022 analysis of 16 supplements, levodopa was undetectable in one. The other 15 contained 2–241 mg per labeled serving.

The range applies to the tested samples. It does not establish the content, clinical effects or safe dose of other products or batches.

Source 6 · Full text read

Official safety summary

RIVM notes that levodopa in Mucuna supplements may cause gastrointestinal symptoms, involuntary movements and psychiatric symptoms. RIVM advises avoiding these supplements during pregnancy, breastfeeding or in case of liver or kidney problems.

The assessment concerns supplements containing seed extract. The data are insufficient to establish a safe dose or the frequency of adverse effects.

Source 8 · Official summary read

Our evidence and source methodology

Mucuna Pruriens: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Mucuna Pruriens?

Mucuna pruriens is a tropical legume plant known as "Atmagupta" or "Kapikachhu" in Indian traditional medicine (Ayurveda). It grows naturally in the temperate regions of India, Africa and the Caribbean. It has been used in Ayurveda for thousands of years for nervous system support, male fertility and vitality.

Levodopa is a dopamine precursor. Its presence in seeds or extracts does not establish cognitive benefit in healthy people.

Mechanism of Effect

Mucuna Pruriens: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans. This schematic mechanism illustration does not establish clinical benefit in humans, a receptor reset or a safe dosing schedule.

⚠ Pharmacological Potency - Drug Interaction Warning

Since Mucuna contains a direct dopamine precursor, it may have serious pharmacodynamic interactions with Parkinson's drugs (Carbidopa/Levodopa combinations). In addition, concomitant use with MAO inhibitors, antipsychotics and other dopaminergic agents may be dangerous. Individuals using any medication should NEVER start Mucuna supplements without obtaining doctor's approval.

Clinical Evidence

Clinical research on Mucuna pruriens focuses on two main areas: Parkinson's disease and male fertility.

Katzenschlager et al. (2004) compared single 15/30 g doses of Mucuna seed preparation with levodopa/carbidopa in eight Parkinson patients. The 30 g preparation had faster onset and longer “on” time; dyskinesia and tolerability did not differ significantly. This small single-dose study does not establish superior long-term safety.

Shukla et al. (2010) used 5 g/day seed powder for three months in infertile men; this is not 5 g of a 15% L-DOPA standardized extract or a 750 mg L-DOPA dose. Findings in this patient group do not establish a safe/effective starting dose for mood or motivation in healthy people. L-DOPA content can vary between products; clinical assessment is needed.

Dose information and research limits

The range applies to the tested samples. It does not establish the content, clinical effects or safe dose of other products or batches.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Katzenschlager R, et al. (2004). Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery & Psychiatry, 75(12), 1672–1677. PubMed · PMID 15548480
  2. Shukla KK, et al. (2009). Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertility and Sterility, 92(6), 1934–1940. PubMed · PMID 18973898
  3. Lieu CA, et al. (2010). A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism & Related Disorders, 16(7), 458–465. PubMed · PMID 20570206
  4. Manyam BV, et al. (2004). Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytotherapy Research, 18(9), 706–12. https://doi.org/10.1002/ptr.1514 PubMed · PMID 15478206
  5. Shukla KK, et al. (2010). Mucuna pruriens Reduces Stress and Improves the Quality of Semen in Infertile Men. Evidence-Based Complementary and Alternative Medicine, 7(1), 137–144. https://doi.org/10.1093/ecam/nem171 PubMed · PMID 18955292
  6. Cohen PA, et al. (2022). Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database. JAMA Neurology, 79(10), 1085–1086. https://doi.org/10.1001/jamaneurol.2022.2184 PubMed · PMID 35939305
  7. T.C. Tarım ve Orman Bakanlığı. Bir takviye edici gıdanın onaylı olup olmadığını nereden öğrenebiliriz? (2026). https://guvenilirgida.tarimorman.gov.tr/Haber/Detay/17314 T.C. Tarım ve Orman Bakanlığı
  8. Netherlands National Institute for Public Health and the Environment (RIVM). (2024). Risk assessment of herbal preparations containing seed extracts of Mucuna pruriens. Report 2024-0087. https://www.rivm.nl/publicaties/risk-assessment-of-herbal-preparations-containing-seed-extracts-of-mucuna-pruriens Netherlands National Institute for Public Health and the Environment (RIVM)

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions